Sector News

Trump's latest pharma-fighting plan? Use Twitter to force prices down, manufacturing to U.S.

January 16, 2017
Life sciences

President-elect Donald Trump told the Washington Post that he’ll give Medicare and Medicaid the power to negotiate drug prices, and that he’ll shame pharma into moving manufacturing to the U.S.

Pharma is fast becoming President-elect Donald Trump’s favorite whipping boy. Last month, Trump vowed to bring down drug prices. Last week, he slammed the industry for “getting away with murder.” And Saturday, he promised the Washington Post he’d subjugate drugmakers with the power of the tweet.

“They’re politically protected, but not anymore,” Trump told the newspaper.

Whereas Trump last week declared he’d institute competitive bidding to control the prices government programs pay for drugs, he reverted over the weekend to Medicare price negotiation, a mainstream proposal he’d backed during his campaign.

This time, the president-elect told the Post that he’d push for price negotiation in both Medicare and Medicaid, though the latter program is already entitled to pharma’s lowest prices.

Medicare is quite different. In fact, the legislation that created Medicare Part D, the popular prescription drug coverage for seniors, explicitly prohibited price negotiation. Proposals to change that rule have failed in Congress ever since.

Trump has claimed that Medicare could save $300 billion a year by negotiating drug prices. “We don’t do it,” he said during last year’s campaign. “Why? Because of the drug companies.”

But though targeting price negotiation may be a well worn idea in Washington, Trump promises to push the idea his own way—“just like on the airplane,” he told the Post, referring to his tweets criticizing the cost of a Lockheed Martin fighter jet. The aircraft makers’ shares tanked on Trump’s social-media attack.

Trump said he didn’t care whether his public arm-twisting sent stocks reeling, as biopharma shares did last week after his vitriolic press conference.

The incoming president also echoed previous comments about overseas drug manufacturing—a common Trump theme, but one that’s previously been focused on car companies such as Ford Motor Co. and other equipment makers, notably the air conditioning and refrigeration company Carrier.

The U.S. “needs to get our drug industry back,” Trump said during last Wednesday’s press conference. “They don’t make them here for a large extent.” To the Post, he said drugmakers “should produce” more of their meds in the U.S.

Pharma companies manufacture many products in the U.S., but also maintain enormous production capacity overseas—some designed to serve local and regional markets, the rest to supply countries around the globe. Many generic drugs are produced in India, where cheap labor helps hold costs—and prices—down.

Trump’s latest pharma comments were part of a Post interview in which the president-elect said he was down to the “final strokes” on his plan to replace the Affordable Care Act. His plan will provide “insurance for everybody” at a much lower cost and with lower deductibles than Obamacare, the president-elect claimed.

“It’ll be another plan,” Trump said in the interview. “But they’ll be beautifully covered.”

By Tracy Staton

Source: Fierce Biotech

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).